News Sentiment

VRAX sentiment intelligence

Virax Biolabs Group Limited Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.08 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+30.4% over one week, -11.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

VRAX SEC Filings - Virax Biolabs Group Ltd 10-K, 10-Q, 8-K Forms

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 30.4% Price confirming higher
Trend fit Trend inactive -11.3% over four weeks
Fair value -87.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 31
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 8
TipRanks 5
PR Newswire 5
Sahm 4
Quiver Quantitative 4
The Globe and Mail 4
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 9
Deals and strategy 3
Macro sensitivity 3
Balance sheet 2
Regulatory and legal 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Stock Titan Direct company coverage

Armistice Capital amends Schedule 13G, holds 1,000,239 VRAX shares (VRAX)

Armistice Capital, LLC and Steven Boyd have filed an amendment to Schedule 13G, disclosing beneficial ownership of 1,000,239 ordinary shares of Virax Biolabs Group Limited (VRAX), representing 4.99% of the class. The shares are directly held by Armistice Capital Master Fund Ltd.,

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 15:14
Source
Stock Titan
Quiver Quantitative Direct company coverage

Virax Biolabs Group Limited Or Stock Short Interest Rises to 71.68%

Short interest in Virax Biolabs Group Limited (VRAX) surged to 71.68% of the float as of April 15th, representing a significant increase from March 31st and indicating a high level of bearish sentiment. Institutional investor activity shows a mixed picture, with some funds reduci

Tone
Negative 38/100
Event
Market update
Published
25 Apr 2026 13:29
Source
Quiver Quantitative
The Globe and Mail Direct company coverage

Virax Biolabs CEO Sets Near-Term Milestones as ViraxImmune Strategy Advances and Valuation Lags

Virax Biolabs Group Limited, an immunology-focused biotech, is concentrating its efforts on ViraxImmune, a T cell immune-profiling assay for post-acute infection syndromes. The company's CEO, James Foster, outlined near-term milestones including a key PAIS data readout and U.S. c

Tone
Positive 71/100
Event
Market update
Published
19 Apr 2026 18:10
Source
The Globe and Mail
Sahm Direct company coverage

Pre-Bell Movers | VRAX Surges by 82.6%; Here Are 20 Stocks Moving Premarket (Apr/13)

This article highlights significant pre-market stock movements on April 13th, 2026, noting that Virax Biolabs Group Ltd. Class A (VRAX.US) surged by 82.6%. It also details broader market reactions to geopolitical tensions, including a rise in WTI crude oil and drops in major tech

Tone
Positive 82/100
Event
Market update
Published
16 Apr 2026 17:09
Source
Sahm
Sahm Direct company coverage

12 Health Care Stocks Moving In Monday's Pre-Market Session

This article lists 12 healthcare stocks that experienced significant price movements in Monday's pre-market session. It highlights both gainers, such as Virax Biolabs Group and Allogene Therapeutics, and losers, including Replimune Group and Beyond Air, detailing their stock chan

Tone
Neutral 50/100
Event
Market update
Published
13 Apr 2026 10:40
Source
Sahm
TipRanks Direct company coverage

Virax Biolabs Announces Full Exercise of Pre-Funded Warrants From $5 Million Private Placement

Virax Biolabs Group Ltd. announced the full exercise of pre-funded warrants from a $5 million private placement initiated in December 2025. This exercise, completed by April 10, 2026, increased the company's ordinary shares outstanding to 19,923,432, converting the financing into

Tone
Positive 66/100
Event
Market update
Published
10 Apr 2026 21:02
Source
TipRanks
The Globe and Mail Direct company coverage

Virax Biolabs Shareholders Approve Reverse Split, New Charter and 2026 Equity Plan After Adjourned AGM

Virax Biolabs Group Ltd. shareholders approved a reverse stock split, an updated charter, and a 2026 Equity Incentive Plan during its recently reconvened annual general meeting on March 18, 2026. These strategic moves aim to streamline the company's capital structure and support

Tone
Neutral 50/100
Event
Market update
Published
02 Apr 2026 05:39
Source
The Globe and Mail
Stock Titan Direct company coverage

Director Nelson Haight reports Virax Biolabs (VRAX) stock option awards

Virax Biolabs Group Ltd director Nelson M. Haight has reported his initial beneficial ownership of various stock option awards. These options, granted under the company's 2023 and 2024 Equity Incentive Plans, have different exercise prices, expiration dates, and vesting schedules

Tone
Neutral 50/100
Event
Market update
Published
31 Mar 2026 19:39
Source
Stock Titan
Sahm Direct company coverage

What's Behind The Jump In Virax Biolabs Stock?

Shares of Virax Biolabs Group are soaring after its wholly-owned subsidiary, Virax Biolabs (UK) Limited, achieved ISO 13485:2016 and ISO 9001:2015 certifications for its quality management system. These certifications lay the foundation for quality-managed development activities,

Tone
Positive 69/100
Event
Market update
Published
31 Mar 2026 18:09
Source
Sahm
Stock Titan Direct company coverage

Virax Biolabs (NASDAQ: VRAX) COO discloses multiple long-dated stock options

Virax Biolabs (NASDAQ: VRAX) Chief Operating Officer, Nigel William McCracken, filed an initial Form 3, disclosing his holdings of multiple long-dated stock options. These options, granted under the company's 2023 and 2024 Equity Incentive Plans, have varying exercise prices and

Tone
Neutral 50/100
Event
Market update
Published
21 Mar 2026 14:38
Source
Stock Titan
Stock Titan Direct company coverage

Virax Biolabs (VRAX) director files initial insider ownership report

Virax Biolabs Group Ltd director Miller Iain David has filed a Form 3, an initial statement of beneficial ownership, with the SEC. This filing establishes his starting equity position as an insider of the company, confirming his role as a director. The Form 3 does not indicate an

Tone
Neutral 50/100
Event
Market update
Published
19 Mar 2026 14:38
Source
Stock Titan